Liposome-encapsulated Doxorubicin (Myocet) Plus Cyclophosphamide as First or Second Line Therapy for Older Patients With Metastatic Breast Cancer
Latest Information Update: 10 Oct 2015
At a glance
- Drugs Cyclophosphamide (Primary) ; Doxorubicin liposomal (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 06 Oct 2015 Status changed from recruiting to discontinued, as reported by ClinicalTrials.gov.
- 25 Sep 2015 Planned End Date changed from 1 Mar 2014 to 1 Feb 2016 as reported by ClinicalTrials.gov.
- 25 Sep 2015 Planned primary completion date changed from 1 Mar 2014 to 1 Feb 2016 as reported by ClinicalTrials.gov.